The Canadian Ministry of Health has authorized the conditional marketing of ficloride-ramdisevir to treat Covid-19, becoming the first approved treatment for the emerging coronavirus in Canada.
The drug company "Gilad Sciences Canada" said in a statement, today, Wednesday, that the drug "is prescribed for the treatment of (COFED-19) in adults and adolescents aged 12 years and over who weigh 40 kilograms or more and who have pneumonia who need oxygen therapy."
The statement pointed out that the study of the use of this drug in hospitals has been studied in patients suffering from the disease in advanced stages of severity.
The Canadian Ministry of Health confirms that it will continue to monitor the safety of the drug in Canada closely and will respond quickly to any safety concerns.
The conditional marketing permit issued by the Canadian Ministry of Health is based on the results of the third phase of global trials conducted by the American National Institute of Allergy and Infectious Diseases.